Table 1.
Characteristics of 24 patients who suffered from COVID-19 during the first 60 d after kidney transplantation.
| Variable | Alive (n = 13) | Dead (n = 11) | p value |
|---|---|---|---|
| Male, n (%) | 6 (46.2) | 5 (45.5) | 0.97 |
| Median age, yr (range) | 61.1 (40–74) | 69.6 (60–75) | 0.006 |
| Age ≥65 yr, n (%) | 4 (30.8) | 8 (72.7) | 0.04 |
| Hypertension, n (%) | 12 (92.3) | 10 (90.9) | 1 |
| Diabetes, n (%) | 8 (66,7) | 4 (36.4) | 0.15 |
| Deceased donor, n (%) | 13 (100) | 10 (91) | 0,46 |
| Delayed graft function n (%) | 5 (38.5) | 7 (63.6) | 0.41 |
| Acute rejection, n (%) | 2 (15.4) | 0 (0) | 0.48 |
| Median time from KT to COVID-19 Dx, d (range) | 39 (15–59) | 28.8 (8–56) | 0.07 |
| Baseline immunosuppressive treatment, n (%) | |||
| Prednisone | 13 (100) | 11 (100) | 1 |
| Tacrolimus | 13 (100) | 11 (100) | 1 |
| Mycophenolate | 12 (92,3) | 9 (81.8) | 0.58 |
| mTOR inhibitors | 0 (0) | 2 (18.2) | 0.2 |
| Fever, n (%) | 9 (69.2) | 6 (54.5) | 0.67 |
| Cough, expectoration, and/or rhinorrhea, n (%) | 6 (46.2) | 8 (72.7) | 0.24 |
| Dyspnea, n (%) | 6 (46.2) | 8 (72.7) | 0.24 |
| Pneumonia, n (%) | 12 (92.3) | 10 (90.9) | 1 |
| Digestive symptoms, n (%) | 1 (7.7) | 2 (18.2) | 0.58 |
| Lymphopenia, n (%) | 13 (100) | 11 (100) | 1 |
| Hospitalization, n (%) | 13 (100) | 11 (100) | 1 |
| Renal failure, n (%) | 6 (46.2) | 7 (63.6) | 0.26 |
| Ventilator support, n (%) | 2 (15.4) | 7 (77.8) | 0.007 |
| Intensive care unit admission, n (%) | 2 (15.4) | 2 (18.2) | 1 |
| COVID-19 treatment, n (%) | |||
| Hydroxychloroquine | 12 (92.3) | 10 (90.9) | 1 |
| Glucocorticoids | 3 (25) | 9 (81.8) | 0.006 |
| Lopinavir/ritonavir | 4 (30.8) | 4 (36.4) | 1 |
| Tocilizumab | 5 (38.5) | 3 (27.3) | 0.68 |
| Median time from admission to death or recovery, d (range) | 23 (4–48) | 13.7 (6–36) | 0.08 |
KT = kidney transplantation; Dx = diagnosis.